Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Equity Income (2018 - 2022)

Theravance Biopharma (TBPH) has disclosed Equity Income for 5 consecutive years, with $28.1 million as the latest value for Q2 2022.

  • Quarterly Equity Income rose 28.28% to $28.1 million in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $118.8 million through Jun 2022, up 64.9% year-over-year, with the annual reading at $104.0 million for FY2021, 51.94% up from the prior year.
  • Equity Income for Q2 2022 was $28.1 million at Theravance Biopharma, up from $25.1 million in the prior quarter.
  • The five-year high for Equity Income was $35.3 million in Q4 2021, with the low at $686000.0 in Q1 2018.
  • Average Equity Income over 5 years is $15.0 million, with a median of $13.5 million recorded in 2020.
  • The sharpest move saw Equity Income soared 808.02% in 2019, then increased 2.55% in 2021.
  • Over 5 years, Equity Income stood at $5.4 million in 2018, then surged by 119.47% to $11.9 million in 2019, then soared by 69.05% to $20.1 million in 2020, then soared by 75.31% to $35.3 million in 2021, then decreased by 20.33% to $28.1 million in 2022.
  • According to Business Quant data, Equity Income over the past three periods came in at $28.1 million, $25.1 million, and $35.3 million for Q2 2022, Q1 2022, and Q4 2021 respectively.